Coulter Partners places Vice President of Intellectual Property at Amphista Therapeutics

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health and Tech, recently partnered with Amphista Therapeutics to further strengthen their team in Cambridge with the appointment of Dr Victoria Lovatt as Vice President of Intellectual Property.

Amphista Therapeutics is a leader in next generation targeted protein degradation (TPD) approaches and is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in TPD that address the challenges faced by earlier stage TPD research, and to realize the full therapeutic potential of this transformational approach. 

Victoria is an IP strategist who brings a wealth of expertise from her experience working across the globe in the biotech and pharmaceuticals sectors.

Nicola Thompson, CEO of Amphista, comments: “I am delighted to welcome Victoria as our Vice President of Intellectual Property. Her specialist knowledge will support us as we continue our work to unlock the full potential of next generation TPD technology in order to bring transformative medicines to patients.”

She adds: “We would like to thank the team at Coulter Partners for their support in securing Victoria’s appointment; we were highly impressed with their professional expertise and extensive market knowledge.”

Victoria joins Amphista from Mundipharma where she was Director of IP Strategy. Prior to that, she held IP roles across the biotechnology and pharmaceutical industries. Victoria is a chartered UK patent attorney, a European patent attorney and a Singapore patent attorney. She holds a BSc (Hons) in Chemistry/Biochemistry from Nottingham University, UK and a PhD in Neuroimmunology from the University of Cambridge, UK.

Commenting on her appointment, Victoria remarks: “I am delighted to join Amphista’s world class team. Amphista is founded on transformational science and I’m looking forward to building on strong IP foundations to develop a broad strategic IP portfolio as we execute our mission of building the leading TPD company.”